PMID- 11588189
DA - 20011005
DCOM- 20011101
IS - 1529-2401
VI - 21
IP - 20
DP - 2001 Oct 15
TI - Selective immunolesions of cholinergic neurons in mice: effects on neuroanatomy, neurochemistry, and behavior.
PG - 8164-73 AB - The ability to selectively lesion mouse basal forebrain cholinergic neurons would permit experimental examination of interactions between cholinergic functional loss and genetic factors associated with neurodegenerative disease. We developed a selective toxin for mouse basal forebrain cholinergic neurons by conjugating saporin (SAP), a ribosome-inactivating protein, to a rat monoclonal antibody against the mouse p75 nerve growth factor (NGF) receptor (anti-murine-p75). The toxin proved effective and selective in vitro and in vivo. Intracerebroventricular injections of anti-murine-p75-SAP produced a dose-dependent loss of choline acetyltransferase (ChAT) activity in the hippocampus and neocortex without affecting glutamic acid decarboxylase (GAD) activity. Hippocampal ChAT depletions induced by the immunotoxin were consistently greater than neocortical depletions. Immunohistochemical analysis revealed a dose-dependent loss of cholinergic neurons in the medial septum (MS) but no marked loss of cholinergic neurons in the nucleus basalis magnocellularis after intracerebroventricular injection of the toxin. No loss of noncholinergic neurons in the MS was apparent, nor could we detect loss of noncholinergic cerebellar Purkinje cells, which also express p75. Behavioral analysis suggested a spatial learning deficit in anti-murine-p75-SAP-lesioned mice, based on a correlation between a loss of hippocampal ChAT activity and impairment in Morris water maze performance. Our results indicate that we have developed a specific cholinergic immunotoxin for mice. They also suggest possible functional differences in the mouse and rat cholinergic systems, which may be of particular significance in attempts to develop animal models of human diseases, such as Alzheimer's disease, which are associated with impaired cholinergic function.
AD - Department of Biological Sciences, Wellesley College, Wellesley,
[emd]
FAU - Berger-Sweeney, J
AU - Berger-Sweeney J
FAU - Stearns, N A
AU - Stearns NA
FAU - Murg, S L
AU - Murg SL
FAU - Floerke-Nashner, L R
AU - Floerke-Nashner LR
FAU - Lappi, D A
AU - Lappi DA
FAU - Baxter, M G
AU - Baxter MG
LA - eng
PT - Journal Article
CY - United States
TA - J Neurosci
JID - 8102140
RN - 0 (Antibodies, Monoclonal)
RN - 0 (Immunotoxins)
RN - 0 (Plant Proteins)
RN - 0 (Receptor, Nerve Growth Factor)
RN - 0 (saporin)
RN - EC 2.3.1.6 (Choline O-Acetyltransferase)
RN - EC 4.1.1.15 (Glutamate Decarboxylase)
SB - IM
MH - Animal
MH - Antibodies, Monoclonal/chemistry
MH - Antibody Specificity
MH - Behavior, Animal/*drug effects/physiology
MH - Cell Count
MH - Cell Survival/drug effects
MH - Cells, Cultured
MH - Choline O-Acetyltransferase/deficiency/metabolism
MH - Corpus Striatum/cytology/drug effects/metabolism
MH - Dose-Response Relationship, Drug
MH - Female
MH - Glutamate Decarboxylase/metabolism
MH - Hippocampus/cytology/drug effects/metabolism
MH - Immunohistochemistry
MH - Immunotoxins/*administration & dosage/chemistry
MH - Injections, Intraventricular
MH - Male
MH - Maze Learning/drug effects
MH - Mice
MH - Mice, Inbred C57BL
MH - Neocortex/cytology/drug effects/metabolism
MH - Neurons/cytology/*drug effects/metabolism
MH - Plant Proteins/chemistry
MH - Prosencephalon/cytology/*drug effects/metabolism
MH - Receptor, Nerve Growth Factor/*antagonists & inhibitors/biosynthesis
MH - Support, Non-U.S. Gov't
EDAT- 2001/10/06 10:00
MHDA- 2001/11/03 10:01
AID - 21/20/8164 [pii]
URLF- http://www.jneurosci.org/cgi/content/full/21/20/8164
URLS- http://www.jneurosci.org/cgi/content/abstract/21/20/8164
PST - ppublish
SO - J Neurosci 2001 Oct 15;21(20):8164-73.